Maveropepimut-S (MVP-S; formerly DPX-Survivac) plus low-dose cyclophosphamide provided clinical benefit to patients with recurrent ovarian cancer, regardless of platinum sensitivity or BRCA mutational status. The durable, survivin-specific T-cell responses observed with the combination further support the continued investigation of peptide cancer vaccine in those with platinum-resistant disease, according to Oliver Dorigo, MD, PhD.
The phase 1b/2, multicenter DeCidE1 trial (NCT02785250) was designed to evaluate MVP-S combined with intermittent low dose of cyclophosphamide in patients with recurrent, epithelial ovarian, fallopian tube, or peritoneal cancer.
Findings, which were presented at the 2023 SGO Annual Meeting on Women’s Cancer, demonstrated that the combination generated an overall response rate of 21% and a disease control rate of 63% in patients with recurrent ovarian cancer. The median time…
